Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CervoMed (CRVO) Cash from Financing Activities (2022 - 2024)

Historic Cash from Financing Activities for CervoMed (CRVO) over the last 9 years, with Q3 2024 value amounting to -$13340.0.

  • CervoMed's Cash from Financing Activities fell 10011.87% to -$13340.0 in Q3 2024 from the same period last year, while for Sep 2025 it was -$106715.0, marking a year-over-year decrease of 10095.83%. This contributed to the annual value of $46.4 million for FY2024, which is 31616.41% up from last year.
  • CervoMed's Cash from Financing Activities amounted to -$13340.0 in Q3 2024, which was down 10011.87% from -$93375.0 recorded in Q4 2023.
  • CervoMed's Cash from Financing Activities' 5-year high stood at $11.2 million during Q3 2023, with a 5-year trough of -$93375.0 in Q4 2023.
  • Its 3-year average for Cash from Financing Activities is $2.2 million, with a median of -$5000.0 in 2022.
  • Per our database at Business Quant, CervoMed's Cash from Financing Activities surged by 22494978.0% in 2023 and then tumbled by 10011.87% in 2024.
  • Quarter analysis of 3 years shows CervoMed's Cash from Financing Activities stood at -$5000.0 in 2022, then tumbled by 1767.5% to -$93375.0 in 2023, then soared by 85.71% to -$13340.0 in 2024.
  • Its Cash from Financing Activities was -$13340.0 in Q3 2024, compared to -$93375.0 in Q4 2023 and $11.2 million in Q3 2023.